STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) and laser-based procedures, such as LASIK to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serve… Read more
STAAR Surgical Company (STAA) - Net Assets
Latest net assets as of September 2025: $353.78 Million USD
Based on the latest financial reports, STAAR Surgical Company (STAA) has net assets worth $353.78 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($456.36 Million) and total liabilities ($102.58 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $353.78 Million |
| % of Total Assets | 77.52% |
| Annual Growth Rate | N/A |
| 5-Year Change | 101.47% |
| 10-Year Change | 922.85% |
| Growth Volatility | 707.38 |
STAAR Surgical Company - Net Assets Trend (1988–2024)
This chart illustrates how STAAR Surgical Company's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for STAAR Surgical Company (1988–2024)
The table below shows the annual net assets of STAAR Surgical Company from 1988 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $397.33 Million | +2.95% |
| 2023-12-31 | $385.95 Million | +14.83% |
| 2022-12-31 | $336.11 Million | +29.99% |
| 2021-12-31 | $258.56 Million | +31.10% |
| 2020-12-31 | $197.22 Million | +23.35% |
| 2019-12-31 | $159.88 Million | +20.73% |
| 2018-12-31 | $132.43 Million | +208.43% |
| 2017-12-31 | $42.94 Million | +13.27% |
| 2016-12-31 | $37.91 Million | -2.42% |
| 2015-12-31 | $38.85 Million | +4.71% |
| 2014-12-31 | $37.10 Million | -4.51% |
| 2013-12-31 | $38.85 Million | +22.40% |
| 2012-12-31 | $31.74 Million | +7.75% |
| 2011-12-31 | $29.46 Million | +31.35% |
| 2010-12-31 | $22.43 Million | +6.44% |
| 2009-12-31 | $21.07 Million | +31.47% |
| 2008-12-31 | $16.03 Million | -55.76% |
| 2007-12-31 | $36.23 Million | +14.06% |
| 2006-12-31 | $31.76 Million | -21.32% |
| 2005-12-31 | $40.37 Million | +6.61% |
| 2004-12-31 | $37.86 Million | +6.89% |
| 2003-12-31 | $35.42 Million | +15.57% |
| 2002-12-31 | $30.65 Million | -34.55% |
| 2001-12-31 | $46.83 Million | -20.18% |
| 2000-12-31 | $58.67 Million | +10.28% |
| 1999-12-31 | $53.20 Million | +9.47% |
| 1998-12-31 | $48.60 Million | +8.48% |
| 1997-12-31 | $44.80 Million | +22.40% |
| 1996-12-31 | $36.60 Million | +27.53% |
| 1995-12-31 | $28.70 Million | +30.45% |
| 1994-12-31 | $22.00 Million | +83.33% |
| 1993-12-31 | $12.00 Million | +64.38% |
| 1992-12-31 | $7.30 Million | +69.77% |
| 1991-12-31 | $4.30 Million | +4200.00% |
| 1990-12-31 | $100.00K | +101.25% |
| 1989-12-31 | $-8.00 Million | -100.00% |
| 1988-12-31 | $-4.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to STAAR Surgical Company's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5457600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $493.00K | 0.12% |
| Other Comprehensive Income | $-7.03 Million | -1.77% |
| Other Components | $471.45 Million | 118.65% |
| Total Equity | $397.33 Million | 100.00% |
STAAR Surgical Company Competitors by Market Cap
The table below lists competitors of STAAR Surgical Company ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A
SHG:688221
|
$548.84 Million |
|
JOHNSON SVC. LS-10
F:5K7
|
$548.86 Million |
|
Eastman Kodak Co
NYSE:KODK
|
$548.99 Million |
|
Alerus Financial Corp
NASDAQ:ALRS
|
$549.02 Million |
|
Universal Health Realty Income Trust
NYSE:UHT
|
$548.70 Million |
|
Raffles Medical Group Ltd
F:02M1
|
$548.22 Million |
|
Xiamen Port Development Co Ltd
SHE:000905
|
$548.17 Million |
|
Odontoprev S.A
SA:ODPV3
|
$548.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in STAAR Surgical Company's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 385,954,000 to 397,335,000, a change of 11,381,000 (2.9%).
- Net loss of 20,208,000 reduced equity.
- Share repurchases of 1,505,000 reduced equity.
- New share issuances of 2,000 increased equity.
- Other comprehensive income decreased equity by 2,918,000.
- Other factors increased equity by 36,010,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-20.21 Million | -5.09% |
| Share Repurchases | $1.50 Million | -0.38% |
| Share Issuances | $2.00K | +0.0% |
| Other Comprehensive Income | $-2.92 Million | -0.73% |
| Other Changes | $36.01 Million | +9.06% |
| Total Change | $- | 2.95% |
Book Value vs Market Value Analysis
This analysis compares STAAR Surgical Company's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.21x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1988-12-31 | $-1.60 | $17.85 | x |
| 1989-12-31 | $-2.90 | $17.85 | x |
| 1990-12-31 | $0.02 | $17.85 | x |
| 1991-12-31 | $0.46 | $17.85 | x |
| 1992-12-31 | $0.72 | $17.85 | x |
| 1993-12-31 | $0.96 | $17.85 | x |
| 1994-12-31 | $2.12 | $17.85 | x |
| 1995-12-31 | $2.10 | $17.85 | x |
| 1996-12-31 | $2.65 | $17.85 | x |
| 1997-12-31 | $3.21 | $17.85 | x |
| 1998-12-31 | $3.38 | $17.85 | x |
| 1999-12-31 | $3.59 | $17.85 | x |
| 2000-12-31 | $3.80 | $17.85 | x |
| 2001-12-31 | $2.73 | $17.85 | x |
| 2002-12-31 | $1.78 | $17.85 | x |
| 2003-12-31 | $1.99 | $17.85 | x |
| 2004-12-31 | $1.93 | $17.85 | x |
| 2005-12-31 | $1.70 | $17.85 | x |
| 2006-12-31 | $1.26 | $17.85 | x |
| 2007-12-31 | $1.29 | $17.85 | x |
| 2008-12-31 | $0.54 | $17.85 | x |
| 2009-12-31 | $0.65 | $17.85 | x |
| 2010-12-31 | $0.64 | $17.85 | x |
| 2011-12-31 | $0.80 | $17.85 | x |
| 2012-12-31 | $0.88 | $17.85 | x |
| 2013-12-31 | $1.01 | $17.85 | x |
| 2014-12-31 | $0.97 | $17.85 | x |
| 2015-12-31 | $0.99 | $17.85 | x |
| 2016-12-31 | $0.94 | $17.85 | x |
| 2017-12-31 | $1.05 | $17.85 | x |
| 2018-12-31 | $2.93 | $17.85 | x |
| 2019-12-31 | $3.41 | $17.85 | x |
| 2020-12-31 | $4.11 | $17.85 | x |
| 2021-12-31 | $5.23 | $17.85 | x |
| 2022-12-31 | $6.81 | $17.85 | x |
| 2023-12-31 | $7.81 | $17.85 | x |
| 2024-12-31 | $8.09 | $17.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently STAAR Surgical Company utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.44%
- • Asset Turnover: 0.62x
- • Equity Multiplier: 1.28x
- Recent ROE (-5.09%) is below the historical average (75.44%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1988 | 0.00% | -55.88% | 0.42x | 0.00x | $-3.40 Million |
| 1989 | 0.00% | -97.78% | 0.34x | 0.00x | $-3.60 Million |
| 1990 | 3500.00% | 77.78% | 0.42x | 106.00x | $3.49 Million |
| 1991 | -262.79% | -262.79% | 0.46x | 2.19x | $-11.73 Million |
| 1992 | -69.86% | -50.00% | 0.80x | 1.75x | $-5.83 Million |
| 1993 | 20.83% | 12.44% | 1.07x | 1.57x | $1.30 Million |
| 1994 | 37.73% | 30.29% | 0.95x | 1.31x | $6.10 Million |
| 1995 | 26.13% | 21.61% | 0.89x | 1.35x | $4.63 Million |
| 1996 | 18.85% | 16.35% | 0.83x | 1.40x | $3.24 Million |
| 1997 | 16.52% | 17.41% | 0.68x | 1.39x | $2.92 Million |
| 1998 | 5.03% | 4.43% | 0.74x | 1.54x | $-2.37 Million |
| 1999 | 4.17% | 3.73% | 0.69x | 1.62x | $-3.07 Million |
| 2000 | -32.33% | -35.01% | 0.67x | 1.37x | $-24.75 Million |
| 2001 | -31.94% | -29.53% | 0.76x | 1.42x | $-19.48 Million |
| 2002 | -56.16% | -35.56% | 1.07x | 1.48x | $-20.21 Million |
| 2003 | -23.73% | -16.56% | 1.07x | 1.34x | $-11.88 Million |
| 2004 | -29.95% | -21.93% | 0.99x | 1.37x | $-15.12 Million |
| 2005 | -27.68% | -21.78% | 0.97x | 1.31x | $-15.21 Million |
| 2006 | -47.37% | -26.73% | 1.18x | 1.50x | $-18.22 Million |
| 2007 | -44.17% | -26.95% | 1.10x | 1.50x | $-19.62 Million |
| 2008 | -144.72% | -30.97% | 1.42x | 3.28x | $-24.80 Million |
| 2009 | -29.43% | -8.23% | 1.28x | 2.79x | $-8.31 Million |
| 2010 | 0.24% | 0.10% | 1.35x | 1.81x | $-2.19 Million |
| 2011 | 4.58% | 2.15% | 1.28x | 1.66x | $-1.60 Million |
| 2012 | -5.55% | -2.76% | 1.16x | 1.73x | $-4.94 Million |
| 2013 | 1.02% | 0.55% | 1.17x | 1.59x | $-3.49 Million |
| 2014 | -22.62% | -11.19% | 1.27x | 1.59x | $-12.10 Million |
| 2015 | -16.82% | -8.47% | 1.23x | 1.62x | $-10.42 Million |
| 2016 | -32.00% | -14.71% | 1.26x | 1.73x | $-15.92 Million |
| 2017 | -4.98% | -2.36% | 1.33x | 1.58x | $-6.43 Million |
| 2018 | 3.75% | 4.01% | 0.74x | 1.26x | $-8.27 Million |
| 2019 | 8.79% | 9.35% | 0.72x | 1.30x | $-1.94 Million |
| 2020 | 3.00% | 3.62% | 0.64x | 1.31x | $-13.81 Million |
| 2021 | 10.64% | 11.94% | 0.67x | 1.34x | $1.66 Million |
| 2022 | 11.80% | 13.95% | 0.68x | 1.25x | $6.05 Million |
| 2023 | 5.53% | 6.62% | 0.66x | 1.27x | $-17.25 Million |
| 2024 | -5.09% | -6.44% | 0.62x | 1.28x | $-59.94 Million |
Industry Comparison
This section compares STAAR Surgical Company's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,683,526,542
- Average return on equity (ROE) among peers: -32.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| STAAR Surgical Company (STAA) | $353.78 Million | 0.00% | 0.29x | $548.73 Million |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $480.24 Million | 2.52% | 0.41x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $-30.16 Million | 0.00% | 0.00x | $16.24 Million |
| Alcon AG (ALC) | $19.68 Billion | 1.70% | 0.48x | $37.82 Billion |
| Align Technology Inc (ALGN) | $3.85 Billion | 10.94% | 0.61x | $11.75 Billion |
| AngioDynamics Inc (ANGO) | $355.71 Million | 3.06% | 0.15x | $354.40 Million |
| Ansell Limited (ANSLF) | $386.33 Million | -0.45% | 0.87x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $8.27 Billion |
| AtriCure Inc (ATRC) | $72.60 Million | -15.79% | 0.54x | $1.42 Billion |
| Avinger Inc (AVGR) | $-35.69 Million | 0.00% | 0.00x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $9.03 Million | -338.35% | 0.77x | $156.14 Million |